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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of antithrombotic therapy in preventing cognitive decline in people with small vessel disease on neuroimaging but
without dementia.
B A C K G R O U N D
Description of the condition
Significance of dementia
Dementia is of huge international concern. Worldwide, over 35
million people have dementia (Prince 2013), with almost half of
all people aged 85+ years living with dementia. The worldwide
annual cost of dementia is over US $600 billion (Wimo 2013). By
2050, it is estimated that the impact of dementia will exceed that
of heart disease, cancer and stroke combined (World Alzheimer
Report 2015). The currently approved treatments for Alzheimer’s
disease only have mild and short-term delaying effects on cog-
nitive decline, and no drug can effectively halt or reverse disease
progression.
Cerebrovascular contribution to Alzheimer’s pathology
Alzheimer’s disease is the commonest form of dementia, char-
acterised by clinical progression with cognitive and physical de-
cline. Despite decades of scientific research, the pathogenesis of
Alzheimer’s disease remains unclear. The “amyloid cascade hypoth-
esis” of Alzheimer’s disease suggests that amyloid-beta accumula-
tion leads to neurofibrillary tangles, which are made up of hyper-
phosphorylated tau aggregation (Jack 2010). More recently, there
is support for a “vascular hypothesis” in Alzheimer’s pathogenesis
(Grammas 2011). Autopsy studies have demonstrated significant
interactions between cerebral aging, cerebrovascular damage and
Alzheimer’s pathology (Iadecola 2010). Vascular risk factors such
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as diabetes, hypertension and adiposity are independent predictors
of Alzheimer’s disease (Akinyemi 2013). Markers of thrombosis,
haemostasis and chronic inflammation are also linked to cogni-
tive decline (Quinn 2011). Cerebrovascular damage can lead to
blood-brain barrier disruption, impaired cerebral blood flow reg-
ulation, hypoxic injury, diminished amyloid-beta clearance, and
neurotoxicity (Janota 2015). Amyloid-beta aggregation, in turn,
can cause further cerebrovascular damage, thus perpetuating the
cycle of neurodegeneration (Chiarini 2015).
Small vessel disease in stroke-free population
Cerebral small vessel disease can be visualised using magnetic res-
onance imaging (MRI) studies as lacunar infarcts, white mat-
ter hyperintensities, and cerebral microbleeds (Boutet 2016; Mok
2015). Positive MRI findings of small vessel disease frequently oc-
cur in patients without a prior history of symptomatic focal neu-
rological deficit such as stroke or transient ischaemic attack (TIA).
Computed tomography (CT) scanning is another clinical tool,
but its diagnostic precision is inferior to that of MRI (Norrving
2015). In one systematic review, 5% to 62% of the population has
MRI evidence of asymptomatic lacunar infarction, especially in
patients with hypertension, carotid stenosis, chronic kidney dis-
ease, metabolic syndrome, heart failure, coronary artery disease,
hyperhomocysteinaemia and obstructive sleep apnoea (Fanning
2014). The overall prevalence of asymptomatic small vessel is-
chaemia (white matter hyperintensities + lacunar infarcts) is much
higher, at 67% in one community-based study (Del Brutto 2015).
Association betweenwhitematter lesions and cognitive decline
White matter lesions can be an early predictor of all types of de-
mentia, with an overall hazard ratio of 2.9 (1.3 to 6.3) in one
large meta-analysis (Montamais 2013), However, this association
is heterogenous, modulated by cognitive reserve, age and spatial
distribution (e.g. periventricular vs. subcortical) of the white mat-
ter lesions. There are no clear associations between the presence
of white matter lesions and the development of dementia in pa-
tients with mild cognitive impairment, or in the general popula-
tion (Montamais 2013). Whilst white matter lesions can impact
upon specific cognitive domains such as executive dysfunction
(Prins 2005), their effects on other domains such as processing
speed and verbal fluency remain unclear (Montamais 2013). The
estimated proportion of dementia with contribution from small
vessel disease ranges from 36% to 67% (Grau-Olivares 2009).
The traditional dichotomisation between Alzheimer’s disease and
vascular dementia subtypes is therefore outmoded and no longer
valid.
Clinical question to be answered
The important clinically-relevant question is this: does this patient
with small vessel disease on neuroimaging, but no prior history of
cardiovascular or cerebrovascular disease, benefit from treatment
with antithrombotic therapy, and if so, which regimen? Many ex-
perts are already calling for improved vascular riskmanagement for
the primary prevention of dementia including Alzheimer’s disease
(Safouris 2015), yet there is little understanding of the effective-
ness of these strategies in altering the trajectory of pathogenesis
and cognitive decline. One of the most widely adopted strategies
for vascular disease prevention is the use of antithrombotic ther-
apy.
Description of the intervention
Antithrombotic therapy consists of antiplatelet agents, oral antico-
agulants, and a combination of these two modalities. Antiplatelet
agents include: inhibition of cyclooxygenase (e.g. aspirin); inhibi-
tion of phosphodiesterases III and V and uptake by red cells of
adenosine (e.g. cilostazol, dipyridamole); blockade of the platelet
ADP P2Y12 receptor (e.g. clopidogrel, prasugrel); blockade of gly-
coprotein IIb/IIIa receptors (e.g. abciximab); and increasing nitric
oxide levels (e.g. triflusal) (Geeganage 2010). Oral anticoagulants
include traditional vitamin K antagonists (e.g. warfarin) and non-
vitamin K oral anticoagulants (NOACs). NOACs include agents
that inhibit activated factor Xa (e.g. apixaban and rivaroxaban) or
thrombin (e.g. dabigatran) (Lip 2015).
How the intervention might work
Antiplatelet agents are the usual treatment for secondary stroke
prevention (ATC 2002), including lacunar (subcortical) stroke
(Kwok 2015). Different regimens have been evaluated in this set-
ting, both as single and combination agents (Ishida 2014). For cer-
tain high-risk patients, such as those with existing cardiovascular
disease (with or without cerebrovascular disease), trials of differ-
ent antiplatelet agents regimens have demonstrated the potential
benefit of dual antiplatelet therapy of aspirin plus clopidogrel over
aspirin monotherapy to prevent stroke (Gouya 2014). However,
the overall effects on stroke prevention (balancing with harm) of
long-term use of dual antiplatelet therapy has not been proven
in patients with ischaemic stroke or TIA (Lee 2013). The use of
antiplatelet agents in patients with small vessel disease needs to
balance the potential benefit against the risk of haemorrhage (Mok
2015).
Oral anticoagulants are the standard treatment for the primary
and secondary prevention of stroke in high-risk patients with non-
valvular atrial fibrillation (Cameron 2014), but not those with
ischaemic attack or minor ischaemic stroke of presumed arterial
origin (De Schryver 2012). NOACs have been shown to be at
least as efficacious and safe as vitamin K antagonists for stroke
prevention in patients with non-valvular atrial fibrillation (Bruins
Slot 2013; Senoo 2015). Combination of antiplatelet agents and
oral anticoagulants has also been investigated for high-risk patients
with atrial fibrillation, and one systematic review concluded that
there was insufficient evidence of its effects in terms of reducing
vascular events (Lane 2013).
Antithrombotic therapy has already been established as the stan-
dard treatment for stroke prevention. We therefore hypothesise
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that antithrombotic therapy might also be effective in preventing
cognitive decline in people with small vessel disease on neuroimag-
ing but without dementia.
Why it is important to do this review
Dementia is a huge public health concern, and currently no inter-
vention can effectively halt or reverse cognitive decline. There is a
clear need to identify effective interventions to alter the trajectory
of cognitive decline and prevent dementia, especially for high-risk
groups such as those with small vessel disease on neuroimaging.
It is unclear whether antithrombotic therapy may be effective in
preventing cognitive decline in people with small vessel disease on
neuroimaging but without dementia.
O B J E C T I V E S
To assess the effects of antithrombotic therapy in preventing cog-
nitive decline in people with small vessel disease on neuroimaging
but without dementia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
We will consider all studies that have recruited people with ev-
idence of small vessel disease on neuroimaging but without de-
mentia:
1. Presence of small vessel disease on neuroimaging - CT or
MRI - including white matter hyperintensities and lacunes of
presumed vascular origin. We will use the definitions of the
STandards for ReportIng Vascular changes on nEuroimaging
(STRIVE) (Wardlaw 2013) as a standard reference and guidance
in this review, but a degree of flexibility of interpretation will be
employed and noted. The presence or absence of cerebral
microbleeds will also be noted.
2. Absence of dementia of any cause as defined by
internationally-accepted diagnostic criteria.
We are also making an assumption that people with recent small
subcortical infarcts would routinely be offered antithrombotic
therapy, and those with visible perivascular spaces, cerebral mi-
crobleeds and brain atrophy would not be routinely be considered
for antithrombotic therapy (Wardlaw 2013).
Types of interventions
Antithrombotic therapy can include the following three treatment
regimens involving two classes of pharmaceutical agents:
1. Antiplatelet agents (e.g. aspirin, dipyridamole, and
clopidogrel - as mono- or combination therapy)
2. Oral anticoagulants (e.g. vitamin K antagonist, direct
thrombin inhibitor, and factor Xa inhibitor)
3. Antiplatelet agent(s) + oral anticoagulant(s).
We will consider all studies that have compared anti-thrombotic
treatment (administered for at least 6 months (180 days)) to no
anti-thrombotic treatment (which may be placebo or treatment as
usual), or that have compared different anti-thrombotic treatment
regimes.
Types of outcome measures
Primary outcomes
1. Change in cognitive function between baseline and final
follow-up using recognised and validated cognitive assessment
measures.
2. Incident dementia of any cause as defined by
internationally-accepted diagnostic criteria.
3. New intracranial haemorrhagic events (including
intracerebral, subdural, subarachnoid and extradural) and
extracranial haemorrhagic events.
Secondary outcomes
1. Functional/vital outcome, e.g. dependency or disability
(using recognised and validated functional assessment measures).
2. Ischaemic stroke or TIA
3. Death
4. Any adverse events
5. Withdrawal from the allocated treatment within the
scheduled follow-up period. This is a composite outcome which
takes into account several factors including adverse events,
compliance and perceived effectiveness.
6. New cerebral microbleeds on neuroimaging.
Search methods for identification of studies
Electronic searches
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We will search ALOIS (www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Review Group’s
Specialised Register, and the Cochrane Stroke Group’s Specialised
Register.
ALOIS is maintained by the Review Group’s Information Spe-
cialist and contains dementia and cognitive improvement studies
identified from:
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
Lilacs
2. Monthly searches of a number of trial registers: meta
Register of Controlled Trials; Umin: Japanese Trial Register;
WHO portal (which covers ClinicalTrials.gov; ISRCTN;
Chinese Clinical Trials Register; German Clinical Trials Register;
Iranian Regsitry of Clinical Trials and the Netherlands National
Trials Register, plus others)
3. Quarterly search of theCochrane Library’s Central Register
of Controlled Trials (CENTRAL)
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Science Conference Proceedings; Index to Theses;
Australasian Digital Theses
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS web site.
Additional separate searches will be run in many of the above
sources to ensure that the most up-to-date results are retrieved.
The search strategy that will be used for the retrieval of reports of
trials from MEDLINE (via the Ovid SP platform) is presented in
Appendix 1.
Searching other resources
Wewill check the reference lists of articles retrieved from the above
searches and, where clarification of information is needed, we will
attempt to contact the investigators of the relevant studies. Impor-
tantly, we anticipate that there may be unpublished cognitive data
of relevance to this review which have been collected in studies
with the primary aim of stroke prevention using antithrombotic
therapy. We will approach experts in the field in order to identify
such data.
Data collection and analysis
Selection of studies
Two review authors will independently screen all of the titles, ab-
stracts, and keywords of publications identified by the searches to
assess their eligibility. Publications that clearly do not meet the
inclusion criteria will be excluded at this stage.We will retrieve the
full-text versions of every study that might possibly be relevant.
Two review authors will independently assess each study accord-
ing to pre-specified selection criteria. Any disagreement will be
resolved by discussion.
Data extraction and management
If studies are included, two review authors will independently ex-
tract the data onto a data extraction form. Any disagreement will
be resolved by discussion. Data reported by the published sources
will be used for the analyses in this review. Where additional out-
come data are needed, we will attempt to contact the investigators
of the studies. In studies that have included a mixed population of
participants with and without dementia, we will attempt to extract
the data from the published sources for those participants without
dementia. If this is not possible, then we will attempt to contact
the investigators of the studies for additional data and clarification.
If this remains not possible, the study will be excluded.
In additional to the important study methodology and outcome
data, we will also extract demographic data (e.g. age and sex distri-
bution, level of cognitive reserve) and possible confounding fac-
tors (e.g. neuroimaging modalities, cognitive assessment methods,
method and duration of treatment, number of participants who
withdraw or are lost during follow-up). Any disagreement will be
resolved by discussion and a consensus decision made.
Assessment of risk of bias in included studies
Risk of bias in included studies will be assessed according to the
guidance in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (http://handbook.cochrane.org/).
Measures of treatment effect
For trialswith comparable primary and secondary outcomes,mean
differences and standardised mean differences, with 95% confi-
dence intervals, will be calculated using a random-effects model.
The differences between treatment groups at final follow-up will
be analysed and the results will be converted into a format suit-
able for meta-analysis. Drug safety and adherence results will be
summarised.
Unit of analysis issues
The participant will be the unit of analysis.
Dealing with missing data
We will contact the investigators of the relevant studies to request
missing data as required. We will use “available case analysis” by
including the data only from those whose results are known, us-
ing as a denominator the total number of people who had data
recorded for the particular outcome in question. Variation in the
degree of missing data across studies will be used as a potential
source of heterogeneity.
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Assessment of heterogeneity
We anticipate a degree of clinical heterogeneity resulting from
differences in participant demographics and baseline cognitive
function. Statistical heterogeneity may also result from differences
in antithrombotic regimens involving different pharmaceutical
agents or classes of agents. Statistical heterogeneity will be as-
sessed according to the guidance in Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (http://hand-
book.cochrane.org/).
Assessment of reporting biases
Reporting bias will be assessed according to the guidance in Chap-
ter 10 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (http://handbook.cochrane.org/).
Data synthesis
For included studies, data analysis will be conducted in accordance
with the guidance in Chapter 11 of theCochraneHandbook for Sys-
tematic Reviews of Interventions (http://handbook.cochrane.org/).
All analyses will be conducted according to intention-to-treat. For
dichotomous data, wewill express relative treatment effects as odds
or risk ratios, as appropriate, with 95% confidence intervals. For
continuous data, we will use mean differences with 95% confi-
dence intervals. A P value of less than 0.05 will be taken as statisti-
cally significant. Where there is no significant clinical or statistical
heterogeneity, and if it appears sensible to combine the results, we
will undertake a meta-analysis using a random-effects model.
Subgroup analysis and investigation of heterogeneity
Planned subgroup analyses will include:
1. People with cognitive impairment vs. cognitively normal
people.
2. People with atrial fibrillation vs. people without atrial
fibrillation.
3. People with prior cardiovascular disease vs. people without
prior cardiovascular disease (including history of stroke and
TIA).
4. Presence vs. absence of cerebral microbleeds.
5. CT vs. MRI as the neuro-imaging tool.
6. Individual drug regimes used in comparison.
Sensitivity analysis
Sensitivity analysis will be undertaken if, for instance, there are
questions about the methodological quality of the included stud-
ies, according to the guidance of Chapter 10 of the Cochrane
Handbook for Systematic Reviews of Interventions (http://hand-
book.cochrane.org/).
Data presentation - ’Summary of findings’ tables
We will use the GRADE (Grades of Recommendation, Assess-
ment,Development andEvaluation) approach to assess the quality
of the supporting evidence behind each estimate of treatment ef-
fect (Schunemann 2011a; Schunemann 2011b). We will present
key findings of the review including a summary of the amount
of data, the magnitude of the effect size and the overall quality
of the evidence, in a ’Summary of findings’ table, created using
GRADEpro software (GRADEpro 2014). We have pre-selected
the following outcomes:
1. Change in cognitive function between baseline and final
follow-up using recognised cognitive assessment measures.
2. Incident dementia of any cause as defined by
internationally-accepted diagnostic criteria.
3. Ischaemic stroke or TIA.
4. Functional/vital outcome e.g. dependency or disability.
5. Any adverse events including intracranial and extracranial
haemorrhagic events.
6. Withdrawal from the allocated treatment.
7. Death.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. (“white matter” adj3 (ischemi* or ischaemi*)).ti,ab.
2. (“micro-bleed*” or microbleed*).ti,ab.
3. *Brain Ischemia/ or *Ischemia/ or White Matter/pathology
4. Leukoencephalopathies/ or Leukoaraiosis/
5. (Microhemorrhage* or Microhaemorrhage*).ti,ab.
6. or/1-5
7. antithrombo*.ti,ab.
8. Aspirin/
9. aspirin.ti,ab.
10. dipyridamole*.ti,ab.
11. Dipyridamole/
12. clopidogrel*.ti,ab.
13. triflusal.ti,ab.
14. prasugrel.ti,ab.
15. ticagrelor.ti,ab.
16. ticlopidine.ti,ab.
17. cilostazol.ti,ab.
18. vorapaxar.ti,ab.
19. abciximab.ti,ab.
20. eptifibatide.ti,ab.
21. tirofiban.ti,ab.
22. terutroban.ti,ab.
23. disgren.ti,ab.
24. plavix.ti,ab.
25. effient.ti,ab.
26. brilinta.ti,ab.
27. ticlid.ti,ab.
28. pletal.ti,ab.
29. zontivity.ti,ab.
30. ReoPro.ti,ab.
31. integrilin.ti,ab.
32. aggrastat.ti,ab.
33. persantine.ti,ab.
34. “acetylsalicylic acid”.ti,ab.
35. “antiplatelet drug*”.ti,ab.
36. Thromboxanes/
37. Glycoproteins/
38. Adenosine Diphosphate/
39. Anticoagulants/
40. Antithrombins/
41. “vitamin k”.ti,ab.
42. phylloquinone.ti,ab.
43. phytomenadione.ti,ab.
44. phytonadione.ti,ab.
45. “thrombin* inhibitor*”.ti,ab.
46. Factor Xa/
47. Fibrinolytic Agents/
48. dabigatran.ti,ab.
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49. rivaroxaban.ti,ab.
50. apixaban.ti,ab.
51. coumarin*.ti,ab.
52. warfarin.ti,ab.
53. Warfarin/
54. Heparin/
55. heparin.ti,ab.
56. phenprocoumon.ti,ab.
57. Acenocoumarol.ti,ab.
58. atromentin.ti,ab.
59. brodifacoum.ti,ab.
60. phenindione.ti,ab.
61. “Xa inhibitor*”.ti,ab.
62. or/7-61
63. 6 and 62
64. (randomized controlled trial or controlled clinical trial).pt. or randomized.tw. or placebo.tw. or clinical trials as topic.sh. or
randomly.tw. or trial.ti.
65. animals/ not humans/
66. 64 not 65
67. 63 and 66
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